CR10784A - Nuevos derivados de aminopirimidina como inhibidores de plki - Google Patents

Nuevos derivados de aminopirimidina como inhibidores de plki

Info

Publication number
CR10784A
CR10784A CR10784A CR10784A CR10784A CR 10784 A CR10784 A CR 10784A CR 10784 A CR10784 A CR 10784A CR 10784 A CR10784 A CR 10784A CR 10784 A CR10784 A CR 10784A
Authority
CR
Costa Rica
Prior art keywords
aminopirimidine
plki
inhibitors
new derivatives
lower alkyl
Prior art date
Application number
CR10784A
Other languages
English (en)
Inventor
Hashiyata Takashi
Kawamura Mikako
Mtsuya Morihiro
Satoh Yoshiyuki
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of CR10784A publication Critical patent/CR10784A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invencion se refiere a un compuesto representado por la Formula [I]: o una sal farmaceuticamente aceptable o ester del mismo, donde cada uno de R1 y R2, que pueden ser iguales o diferentes, es un atomo de hidrogeno, un atomo de halogeno, un grupo alquilo inferior que puede estar sustituido, o un grupo ciclopropilo; cada uno de R3 y R4, que pueden ser iguales o diferentes es un atomo de hidrogeno, un grupo alquilo inferior sustituido con NRaRb.
CR10784A 2006-12-28 2009-05-08 Nuevos derivados de aminopirimidina como inhibidores de plki CR10784A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006356575 2006-12-28
JP2007265783 2007-10-11

Publications (1)

Publication Number Publication Date
CR10784A true CR10784A (es) 2009-09-16

Family

ID=39588592

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10784A CR10784A (es) 2006-12-28 2009-05-08 Nuevos derivados de aminopirimidina como inhibidores de plki

Country Status (24)

Country Link
US (1) US7977336B2 (es)
EP (2) EP2114942B1 (es)
JP (1) JPWO2008081914A1 (es)
KR (1) KR101481388B1 (es)
CN (1) CN101573361B (es)
AR (1) AR064619A1 (es)
AU (1) AU2007340530B2 (es)
BR (1) BRPI0718966B8 (es)
CA (1) CA2668738A1 (es)
CL (1) CL2007003758A1 (es)
CO (1) CO6190523A2 (es)
CR (1) CR10784A (es)
EC (1) ECSP099324A (es)
GT (1) GT200900124A (es)
IL (1) IL198675A0 (es)
MA (1) MA31109B1 (es)
MX (1) MX2009004920A (es)
NO (1) NO20092770L (es)
NZ (1) NZ577273A (es)
PE (1) PE20081845A1 (es)
RU (1) RU2458062C2 (es)
SV (1) SV2009003258A (es)
TW (1) TW200835485A (es)
WO (2) WO2008081910A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009006706A (es) 2006-12-22 2009-07-02 Astex Therapeutics Ltd Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
MX2009006704A (es) 2006-12-22 2009-06-30 Astex Therapeutics Ltd Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
WO2010013633A1 (ja) * 2008-07-31 2010-02-04 萬有製薬株式会社 細胞のｒｂステイタス及びｐｌｋ１阻害剤に対する感受性を予測する方法
JP4489132B2 (ja) * 2008-08-22 2010-06-23 株式会社東芝 磁気記録媒体の製造方法
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
US8445674B2 (en) 2009-10-21 2013-05-21 Hoffmann-La Roche Inc Heterocyclyl compounds
JP5641664B2 (ja) 2009-10-30 2014-12-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ イミダゾ［１，２−ｂ］ピリダジン誘導体およびＰＤＥ１０阻害剤としてのそれらの使用
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
BR112013033375B1 (pt) 2011-06-27 2022-05-10 Janssen Pharmaceutica N.V Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
EP2771337B1 (en) 2011-09-27 2017-08-02 Novartis AG 3-(pyrimidin-4-yl)-oxazolidin-2-ones as inhibitors of mutant idh
AU2013283426B2 (en) 2012-06-26 2018-02-22 Janssen Pharmaceutica Nv Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological or metabolic disorders
WO2014009305A1 (en) 2012-07-09 2014-01-16 Janssen Pharmaceutica Nv Inhibitors of phosphodiesterase 10 enzyme
JP6324381B2 (ja) 2012-07-31 2018-05-16 クラウン バイオサイエンス インコーポレイテッド（タイカン） 抗ｅｇｆｒ薬物による処置のための非小細胞肺癌患者を同定するための組織学的マーカー
WO2014046617A1 (en) * 2012-09-19 2014-03-27 Agency For Science, Technology And Research Compositions and methods for treating cancer
JP6559228B2 (ja) 2014-09-17 2019-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症及び糖尿病の治療に有用なテトラヒドロイソキノリン誘導体及び医薬組成物
WO2018191171A1 (en) * 2017-04-10 2018-10-18 City Of Hope P38 gamma inhibitors and method of use thereof
CN114269742B (zh) * 2019-07-10 2024-07-16 常州千红生化制药股份有限公司 作为治疗剂的4-(咪唑并[1,2-a]吡啶-3-基)-N-(吡啶基)嘧啶-2-胺的衍生物
AU2020318710B2 (en) * 2019-07-24 2025-11-20 Merck Patent Gmbh 4-(imidazo[1,2-a]pyridin-3-yl) -pyrimidine derivatives
CN112592318B (zh) * 2020-12-12 2022-05-03 贵州医科大学 2-(4-甲氨酰基)苯胺基-4-氨基嘧啶衍生物及应用
EP4597104A1 (en) 2022-09-29 2025-08-06 Japanese Foundation For Cancer Research Drug screening method based on drug discovery concept of cancer cell proliferation inhibition induced by disruption of chromosome regulation due to plk1 kinase activation
CN119318874B (zh) * 2024-12-18 2025-04-15 淄博凯美可工贸有限公司 一种节能型复合脱硫剂的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
FI95708C (fi) 1988-10-31 1996-03-11 Eisai Co Ltd Analogiamenetelmä 1,4-diatsepiinijohdannaisen ja sen farmaseuttisesti sopivan suolan valmistamiseksi
JPH045029A (ja) 1990-04-23 1992-01-09 Bridgestone Corp 空気入りタイヤ
DK0547165T3 (da) 1990-09-28 2000-03-27 Smithkline Beecham Corp Fremgangsmåde til fremstilling af vandopløselige camptothecinanaloger såvel som forbindelserne 10-hydroxy-11-C(1-6)-alkoxyc
US5200524A (en) 1990-12-20 1993-04-06 North Carolina State University Camptothecin intermediates and method of making same
US5243050A (en) 1990-12-20 1993-09-07 North Carolina State University Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5191082A (en) 1990-12-20 1993-03-02 North Carolina State University Camptothecin intermediate and method of making camptothecin intermediates
US5247089A (en) 1990-12-20 1993-09-21 North Carolina State University Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5162532A (en) 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
EP0666868B2 (en) 1992-10-28 2006-06-14 Genentech, Inc. Use of anti-VEGF antibodies for the treatment of cancer
JP3025602B2 (ja) 1993-05-21 2000-03-27 デビオファーム エス．アー． 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
EP0831880A4 (en) 1995-06-07 2004-12-01 Imclone Systems Inc ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH
JP3154399B2 (ja) 1996-07-04 2001-04-09 デビオファーム エス．アー． 白金化合物の製造方法
MXPA01007019A (es) * 1999-11-10 2002-09-18 Johnson & Johnson 2-aril-3-(heteroaril)-imidazo[1,2-a]pirimidinas, sustituidas y composiciones farmaceuticas relacionados y metodos.
WO2002046157A2 (en) 2000-12-04 2002-06-13 Sepracor, Inc. Methods for the stereoselective synthesis of substituted piperidines
US7196095B2 (en) 2001-06-25 2007-03-27 Merck & Co., Inc. (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds
CA2455181C (en) 2001-08-01 2010-04-06 Merck & Co., Inc. Benzimidazo[4,5-f]isoquinolinone derivatives
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
WO2004043936A1 (ja) 2002-11-14 2004-05-27 Kyowa Hakko Kogyo Co., Ltd. Ｐｌｋ阻害剤
WO2005092899A1 (en) 2004-03-26 2005-10-06 Methylgene Inc. Inhibitors of histone deacetylase
AU2005278292B2 (en) * 2004-08-31 2011-09-08 Msd K.K. Novel substituted imidazole derivatives

Also Published As

Publication number Publication date
CN101573361A (zh) 2009-11-04
US7977336B2 (en) 2011-07-12
ECSP099324A (es) 2009-06-30
IL198675A0 (en) 2010-02-17
EP2114942A4 (en) 2010-09-08
JPWO2008081914A1 (ja) 2010-04-30
CO6190523A2 (es) 2010-08-19
SV2009003258A (es) 2010-08-23
AU2007340530A1 (en) 2008-07-10
WO2008081914A1 (ja) 2008-07-10
TW200835485A (en) 2008-09-01
CN101573361B (zh) 2012-05-30
MX2009004920A (es) 2009-05-21
PE20081845A1 (es) 2008-12-27
US20080305081A1 (en) 2008-12-11
RU2009128966A (ru) 2011-02-10
MA31109B1 (fr) 2010-01-04
CL2007003758A1 (es) 2008-07-04
EP2114942A1 (en) 2009-11-11
CA2668738A1 (en) 2008-07-10
AU2007340530B2 (en) 2012-09-13
EP2114942B1 (en) 2012-10-31
BRPI0718966B8 (pt) 2021-05-25
BRPI0718966B1 (pt) 2020-11-17
NO20092770L (no) 2009-09-25
GT200900124A (es) 2010-11-03
KR20090092822A (ko) 2009-09-01
EP2116543A4 (en) 2010-09-08
KR101481388B1 (ko) 2015-01-12
EP2116543A1 (en) 2009-11-11
BRPI0718966A2 (pt) 2014-01-07
NZ577273A (en) 2011-03-31
AR064619A1 (es) 2009-04-15
WO2008081910A1 (en) 2008-07-10
RU2458062C2 (ru) 2012-08-10

Similar Documents

Publication Publication Date Title
CR10784A (es) Nuevos derivados de aminopirimidina como inhibidores de plki
DK2091948T3 (da) Nye inhibitorer af glutaminylcyclase
ES2531056T3 (es) Espirociclos como inhibidores de 11-beta hidroxilesteroide deshidrogenasa tipo 1
ECSP11011365A (es) Sales de adición de aminas que contienen grupos hidroxilo y/o carboxílicos con derivados de ácido aminonicotínico como inhibidores de dhodh
PE20181378A1 (es) Compuestos biciclicos derivados de dihidroquinolina-2-ona como inhibidores de cyp11b
CO6150142A2 (es) Bezoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus
ES2600636T3 (es) Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2
PE20211240A1 (es) Inhibidores de endonucleasa cap-dependientes
PE20130155A1 (es) Derivados de ariletinilo
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
CR20150509A (es) Derivados de naftiridina utiles como antagonistas de la alfa-v-beta-6 integrina
BRPI1013821A8 (pt) piridinas substituídas como antagonistas de ccr3.
UY30897A1 (es) Derivados de pentafluorotiobenzamidoacetonitrilo, composiciones conteniéndolos y aplicaciones
PE20151602A1 (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR B(beta)2 ADRENERGICO ASI COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARINICO M3
AR086198A1 (es) Inhibidores sustituidos de acetil-coa carboxilasa y composiciones farmaceuticas que los contienen
CO6400139A2 (es) Derivados de ciclopenta[c]pirool-2-carboxilatos, su preparación y su aplicación en terapéutica
ATE542813T1 (de) 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren
EA201591239A1 (ru) Замещенные фталазин-1(2h)-оновые производные в качестве селективных ингибиторов поли(адф-рибоза)полимеразы-1
AR080596A1 (es) Compuestos alquilamido y composiciones farmaceuticas
CO7151507A2 (es) Compuestos de fenoxietil piperidina
PE20151060A1 (es) Nuevos derivados de pirazina como agonistas del receptor cb2
BR112015015275A2 (pt) composto heterocíclico substituído por halogênio
PE20141579A1 (es) Nuevos 2h-indazoles como antagonistas del receptor ep2
CO2018010787A2 (es) Compuesto de griseofulvina
UY34869A (es) Derivados de pirimidinonas, su preparación y su aplicación en terapéutica.

Legal Events

Date Code Title Description
FC Refusal